Patients excreting large amounts of urinary protein, who are otherwise deemed to be optimally treated, should still be considered at high risk for renal disease progression. The observation that reductions in urinary protein excretion, in a graded fashion over a relatively short period of time, correlate with long-term preservation of renal function supports the idea of using urinary protein excretion as a guide to implementation of renoprotective therapies. The association between residual proteinuria and renal outcomes suggests that minimization of proteinuria is an important therapeutic goal in the management of proteinuric chronic kidney disease patients. This article reviews the evidence for using proteinuria as a target for the implementation of therapies shown to have renal protective effects.

Keywords:
Proteinuria, targeting, Chronic kidney disease, Antiproteinuric therapy
1.
Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974–2984.
2.
Palmer BF: The renal tubule in the progression of chronic renal failure. J Investig Med 1997;45:346–361.
3.
Atkins RC, Briganti EM, Lewis JB, et al: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281–287.
4.
de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309–2320.
5.
Ruggenenti P, Perna A, Remuzzi G: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003;63:2254–2261.
6.
Wright JT Jr, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421–2431.
7.
Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754–762.
8.
Wilmer WA, Rovin BH, Hebert CJ, Rao S, Kumor K, Hebert L: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217–3232.
9.
Jafar TH, Stark PC, Schmid CH, et al: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131–1140.
10.
de Zeeuw D, Remuzzi G, Parving HH, et al: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921–927.
11.
Parving HH, Smidt UM, Hommel E, et al: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993;22:188–195.
12.
Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–2572.
13.
Jafar TH, Stark PC, Schmid CH, et al: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244–252.
14.
Palmer BF: Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002;347:1256–1261.
15.
Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004;65:1991–2002.
16.
Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283–1289.
17.
Hebert LA, Bain RP, Verme D, et al: Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 1994;46:1688–1693.
18.
Wilmer WA, Hebert LA, Lewis EJ, et al: Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999;34:308–314.
19.
Swift PA, Markandu ND, Sagnella GA, He FJ, MacGregor GA: Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. Hypertension 2005;46:308–312.
20.
Jones-Burton C, Mishra SI, Fink JC, et al: An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 2006;26:268–275.
21.
Mishra SI, Jones-Burton C, Fink JC, Brown J, Bakris GL, Weir MR: Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep 2005;7:385–391.
22.
Bakris GL, Weir MR: Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens 1996;9:200S–206S.
23.
Weir MR: Is it the low-protein diet or simply the salt restriction? Kidney Int 2007;71:188–190.
24.
Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272–279.
25.
Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682–1685.
26.
Bakris GL, Smith A: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996;125:201–204.
27.
Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM: Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005;16:474–481.
28.
Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996;124:627–632.
29.
Gansevoort RT, de Zeeuw D, de Jong PE: Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995;10:497–504.
30.
Ruilope LM, Casal MC, Praga M, et al: Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake. J Am Soc Nephrol 1992;3:1307–1311.
31.
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1–290.
32.
Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005;68:1190–1198.
33.
Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C: Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005;16:3038–3045.
34.
Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799–812.
35.
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117–124.
36.
Vecchio L, Procaccio M, Vigano S, Cusi D: Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nature Clin Practice Nephrol 2007;3:42–49.
37.
Douglas K, O’Malley PG, Jackson JL: Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006;145:117–124.
38.
Sandhu S, Wiebe N, Fried LF, Tonelli M: Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006–2016.
39.
Halimi JM, Giraudeau B, Vol S, et al: Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000;58:1285–1292.
40.
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21–28.
41.
Navarro-Diaz M, Serra A, Romero R, et al: Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006;17:S213–S217.
42.
Lea J, Greene T, Hebert L, et al: The relationship between the magnitude of proteinuria reduction and risk of end-stage renal disease. Arch Intern Med 2006;165:947–953.
43.
Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585–592.
44.
Hovind P, Rossing P, Tarnow L, Toft H, Parving J, Parving HH: Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 2001;24:1972–1977.
45.
Rossing K, Christensen PK, Hovind P, Parving HH: Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 2005;48:2241–2247.
46.
Hovind P, Tarnow L, Rossing P, Carstensen B, Parving HH: Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2004;66:1180–1186.
47.
Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601–1608.
48.
de Jong PE, Navis G, de ZD: Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352–353.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.